Similarly, a model of diabetic nephropathy suggested that treatment with pioglitazone reduces glomerular sclerosis, fibrosis, and hypertrophy by lowering ICAM-1, E-selectin, and albuminuria [98,99]. This evidence concerns the gene ICAM1 and glomerulosclerosis.